Oxidative stress (OS) is increased in chronic diseases, including cardiovascular (CV), but there are few data on its effects on the heart and vessels. The isoprostanes (IsoP) are bioactive compounds, with 8-iso-PGF 25α being the most representative in vivo marker of OS. They correlate with the severity of heart failure (HF), but because data regarding OS levels in different types of HF are scarce, our study was aimed to evaluate it by assessing the urinary levels of 8-iso-PGF 2α and its correlations with various biomarkers and parameters. Our prospective study included 53 consecutive patients with HF secondary to ischemic heart disease or dilative cardiomyopathy, divided according to the type of HF (acute, chronic decompensated or chronic compensated HF). The control group included 13 hypertensive patients, effectively treated. They underwent clinical, laboratory -serum NT-proBNP, creatinine, uric acid, lipids, C reactive protein (CRP) and urinary 8-iso-PGF 2α and echocardiographic assessment. HF patients, regardless the type of HF, had higher 8-iso-PGF 2α than controls (267.32pg/µmol vs. 19.82pg/µmol, p<0.001). The IsoP level was directly correlated with ejection fraction (EF) (r=-0.31, p=0.01) and NT-proBNP level (r=0.29, p=0.019). The relative wall thickness (RWT) was negatively correlated with IsoP (r=-0.55, p<0.001). Also 8-iso-PGF 25α was higher by 213.59pg/µmol in the eccentric left ventricular (LV) hypertrophy subgroup comparing with the concentric subgroup (p=0.014), and the subgroups with severe mitral regurgitation (MR) and moderate/ severe pulmonary hypertension (PAH) had the highest 8-iso-PGF 2α levels. Male sex, severe MR, moderate/severe PAH, high LV mass and low RWT values were predictive for high OS level in HF patients.Eccentric cardiac remodeling, MR severity and PAH severity are independent predictors of OS in HF patients.
OS-the imbalance between oxidants i.e. reactive oxygen species (ROS) and antioxidants -is increased in chronic diseases [1, 2] and particularly in cardiovascular diseases (CVD) [3] .
Although the ROS play a well-studied role in CVD pathophysiology -first in atherosclerosis, starting with lipid oxidation [3] and increased vascular production caused by oscillatory shear [4] , and later in heart failure (HF) progression -what is still missing is a thorough understanding of the effects of increased ROS levels on cardiac and vascular tissues.
Recent data has proven a strong connection between OS and the renin-angiotensin-aldosterone system (RAAS) in CV system [5] , kidney and brain [6] mediated by the endothelial mineralocorticoid receptor, allowing a deeper understanting of the upregulation of OS by aldosterone, ultimately leading to myocardial dysfunction.
In vivo evaluation of OS is further hindered by differences in the choice of the biomarkers, tissues used, techniques and available commercial kits. One of the most accurate method * email: ancafarcas@yahoo.com, phone: +40 744780873 to evaluate OS measures the F2-isoprostanes -prostaglandinlike compounds produced in vivo by ciclooxygenaseindependent arachidonic acid oxidation ( fig. 1) [7, 8] .
8-iso-PGF 2α was reported to be the most accurate in vivo OS marker; measuring its urinary level is simple and accurate because it lacks the fatty component, thus the influence of self-oxidation is minimal.
IsoP are not only diagnostic markers but also active molecules with a large spectrum of biological effects: they promote lipid oxidation and local inflammation in atherosclerosis [3] , modulate the fibroblasts and promote collagen production and storage in the myocardial interstitial space [9, 10] .
Various biomarkers -e.g. endotelin-1, cytokines, TNF-α, Creactive protein (CRP) -have proven the increased level of inflammation and endothelial dysfunction. Aldosterone antagonists and statins used in therapy have proven the decrease of inflammation and have shown the correlations between the RAAS, OS, inflammation, myocardial dysfunction and progression of HF [11] [12] [13] . Besides, patients with compensated HF have increased levels of inflammation markers, OS and extracellular matrix degradation that correlate with plasma aldosterone level [14] . To the best of our knowledge there is no published data regarding OS levels in patients with different types of HFacute (de novo) or decompensated. Therefore our study was aimed to evaluate the level of OS in different types of HF by assessing the urinary levels of 8-iso-PGF 2α and its correlation with various biomarkers.
Experimental part
We performed a prospective study that included 53 consecutive patients admitted to the Cardiology Department of the Emergency Clinical County Hospital in Cluj-Napoca with a diagnosis of HF secondary to ischaemic heart disease or dilated cardiomyopathy. We excluded patients with significant valvular diseases -except for those secondary to left ventricular (LV) and/or mitral annular dilatation -acute coronary syndromes, diabetes mellitus, chronic kidney disease -Creatinine clearance (CLcr) <35 mL/min-uncontrolled hypertension and known current malignancies. The control group consisted of 13 patients with controlled hypertension (beta-blocker and/or ACE-inhibitor) with no other CVD.
All patients were informed on study procedures and signed the informed consent. The study was approved by the Ethics Committee of the Iuliu Haieganu University of Medicine and Pharmacy Cluj-Napoca (No. 377/November 3, 2014).
A blood sample and a morning urine sample was collected from each patient. The laboratory markers assessed were: NT-proBNP, serum creatinin, uric acid, total cholesterol, LDLcholesterol, HDL-cholesterol, triglycerides and CRP. CLcr was calculated according to the Cockroft-Gault formula, using serum creatinin, age, weight and gender [15] .
Urine samples were stored in Ependorf vials at -80°C after adding 10µL of hydroxytoluen butilate per each mL of urine as an antioxidant. The 8-iso-PGF 2α was assessed by immunoenzymatic method using a commercially available kit from Cayman Chemical Company, Ann Arbor, Michigan, USA with IC 50 = 10pg/mL and a detection threshold of 2.7pg/ mL. 8-iso-PGF 2α evels were adjusted to the urine creatinine level assessed from the same urine sample using the reaction between urinary creatinine and alkaline picrate (intratest and intertest variability coefficients of 2 and 4%, respectively).
Echocardiography was performed for each patient using a 2-5 MHz transducer on a Siemens Acuson X300 ultrasound machine to evaluate LV structural and performace parameters.
Statistical analysis
Data analysis was performed using R software version 3.2.3 [14] . Demographic, clinical and laboratory characteristics were analyzed for all patients and also stratified for HF type and EF. Data distribution was evaluated using the Shapiro Wilk test. Normal distribution variables were presented as average ± standard deviation while the other as median and interquartile range (IQR). Group comparison was done using the chi-square or Fisher test for categorial variables, Student test for continuous variables with normal distribution and Mann-Whitney U test for ordinal and continuous variables without normal distribution. Comparisons between ≥ 3 independent groups (for quantitative variables without normal distribution) were done using the Kruskal Wallis test, followed by nonparametric post-hoc test. Correlations between quantitative variables were analyzed using Spearman's test (when at least one variable didn't have normal distribution) and Pearson's in all other cases.Univariate linear and multiple regression was performed for the relationship between 8-iso-PGF 2α and independent variables-gender, HF presence and echocardiographic parameters (RWT, LV mass, moderate/ severe MR and moderate/severe PAH). A two -sided p value ≤ 0.05 was deemed statistically significant. Table 1 shows patient demographics. HF patients were older, more frequently males and with longer QRS duration compared to the control group (p<0.05 all). Uric acid and NT-proBNP levels were significantly higher while total cholesterol, LDL-cholesterol, HDL-cholesterol and CLcr were significantly lower compared to the control group (p<0.05 all). We found no significant differences in triglyceride and CRP levels and the prevalence of smoking and alcohol consumption between Regardless of the group, women had significantly lower levels of 8-iso-PGF 2α compared to men (108.97 pg/µmol creatinine vs. 253.57 pg/µmol creatinine, p<0.001). Age, type of medication, presence/absence of smoking and alcohol consumption had no significant effect on the urinary 8-iso-PGF 2α levels (data not shown).
Results and discussions
Although patients in NYHA class IV had the highest levels of 8-iso-PGF 2α , the differences between different NYHA classes were not significant. Urinary 8-iso-PGF 2α levels increased with the lowering of EF; patients with EF > 36% had the lowest level (table 3) . 8-iso-PGF 25α levels in patients with concentric LV hypertrophy (RWT ≥ 0.42) were 213.59 pg/µmol creatinine lower compared to those with eccentric LV hypertrophy (RWT < 0.42) (p=0.014).
Patients with severe MR and moderate/severe PAH had the highest levels of urinary IsoP compared to other grades of MR and PAH, respectively. We found no significant differences between patients with no or mild MR compared to moderate MR and between absent PAH compared to mild PAH. Urinary 8-iso-PGF 2α levels had a significant negative correlation with the body mass index (BMI) (r = -0.43, p < 0.001) and creatinine clearance but not with uric acid, CRP, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides.
We found a positive correlation between urinary 8-iso-PGF 2α and plasma NT-proBNP levels (r=0.29, p= 0.019). Several echocardiographic parameters specific to LV remodeling and LV systolic performance correlated to the 8-iso-PGF 2α levels (table 4). Significant positive correlations were found between urinary 8-iso-PGF 2α levels and LV mass (absolute) (r=0.38, p=0.002), LV mass (indexed) (r=0.47, p=0.001), end-diastolic LV diameter (r=0.39, p=0.001), respectively. Significant negative correlations were found between 8-iso-PGF 2α and RWT (r=-0.31, p=0.01), LV EF (r=-0.55, p<0.001), respectively.
1: acute HF, 2: compensated HF, 3: decompensated HF, 4: control In our study the level of OS-assessed by 8-iso-PGF 2α -was increased in all HF patients compared to those from the control group, similar to published results that show the OS is higher in chronic diseases, particularly in HF [17]. Acute HF patients had the highest urinary 8-iso-PGF 2α levels, possibly due to the major acute imbalance in neurohormonal status and homeostasis. The lowest urinary 8-iso-PGF 25α levels were found in chronic compensated HF patients, suggesting a decrease in the level of OSafter the acute phase of the disease, probably achieved through HF-specific medication and reaching a better hemodynamic status. However, parallel to the worsening of the clinical status and progression of NYHA class, the level of OS increases [18] , also shown by our results. However, the levels of OS in compensated HF patients are significantly higher than in the control patients. Because the control group in our study consisted of hypertensive patients under neurohormonal medication (beta-blockers and/or ACE-I), this allows us to hypothesize that the effect of neurohormonal medication (including aldosterone antagonists) is limited and additional therapeutic options are required to reduce the level of OS in these patients.
Several CV risk factors influence the OS level, such as smoking that significantly increases xanthine oxidase and malondialdehyde levels [19] and decreases vitamins C and E (antioxidants) levels. In our study, age, alcohol and smoking had no major influence on the 8-iso-PGF 2α levels, suggesting that OS in HF patients is caused by the disease itself and its severity and less by the additional factors.
In our study the cause of HF was ischaemic or dilated cardiomyopathy -both having myocite injury and cardiac remodeling as cornerstones, which causes the progression towards HF [20, 21] . ROS levels -increased both in ischemic heart disease [18] and dilated cardiomyopathy [17, 22]induce myofibrillar contractile dysfunction through a number of mechanisms, including decreased nitric oxide bioavailability, decreased â-adrenoreceptor expression [23] and ion channel activity [24] , activation of protein kinases [25] and oxidation of myofibrillar proteins [26] . Besides, our results show the increase in the level of OS parallels the worsening of LV contractile performance (assessed by EF and LV end-diastolic diameter). We believe the most significant result of our study to be the association between LV remodeling (characterized by dilatation, eccentric remodeling and increased myocardial mass) and increased level of oxidative stress. To the best of our knowledge, this is the first study to present this correlation between the level of OS and LV hypertrophy and also that OS is higher in eccentric than in concentric LV hypertrophy.
Besides, LV remodeling, regardless of neurohormonal activation, is a contributor to HF progression through myocyte [26] associated to cardiomyocyte reprogramming of the molecular expression and activation of cytokines and free radicals secretion. Hemodynamic stress of volume and pressure overload caused by severe MR and PAH further deteriorate the molecular myocardial environment by releasing ROS and increasing the level of OS, as shown by the results in our study.
Changes in NT-proBNP and 8-iso-PGF 2α were similar in HF patients, suggesting their dynamics are parallel in these patients and the main cause of their changes is the cardiac dysfunction itself. The positive correlation between 8-iso-PGF 2α and NT-proBNP (the de facto diagnostic and prognostic marker for HF) is another argument supporting the idea that the level of free radicals is higher in patients with advanced HF and measuring the end-products of aerobic metabolism could further improve the evaluation of disease severity and predict the outcome (with the caveat of further studies needed).
In chronic HF the urinary 8-iso-PGF 2α levels correlate with NYHA class [28] , plasma BNP and IL-6 levels [17], thus prompting its possible addition to the list of negative prognostic markers [17, 29, 30] alongside other inflammation [31] and OS [32-34] markers.
The limitations of our study are caused by the rather small number of patients included. We tried to overcome the lack of specificity of the markers of OS by assembling a homogeneous patient group with no other chronic illnesses that could influence the ROS level, except for HF secondary to ischaemic or dilated cardiomyopathy.
Conclusions
In our HF group the level of OS is increased regardless of the type of HF (acute or chronic), the level of HF compensation and the neurohormonal medication. Eccentric cardiac remodeling, MR severity and PAH severity are independent predictors of OS in these patients. The prognostic value of the OS level needs further evaluation.
